CLINICAL UTILITY OF CYFRA 21-1 IN ONCOLOGY: A COMPREHENSIVE REVIEW OF CURRENT EVIDENCE AND FUTURE DIRECTIONS
Abstract
CYFRA 21-1, a soluble fragment of cytokeratin-19 released during epithelial cell apoptosis and necrosis, has emerged as a promising serum biomarker across a wide range of epithelial malignancies. This review synthesizes current evidence regarding its diagnostic, prognostic, and predictive roles in oncology, with emphasis on its clinical applicability, limitations, and future perspectives. Elevated baseline concentrations of CYFRA 21-1 consistently correlate with greater tumor burden, advanced stage, and poorer survival in cancers such as non–small cell lung cancer, head and neck squamous carcinoma, esophageal, colorectal, breast, thyroid, and urothelial tumors. Serial measurement provides additional clinical insight, as reductions during treatment reflect therapeutic response, whereas rising levels may precede radiologic or clinical relapse. Despite these strengths, limited sensitivity in early-stage disease, biological heterogeneity, and lack of assay standardization currently restrict universal application. Integrative approaches combining CYFRA 21-1 with complementary tumor markers, inflammatory indices, or molecular assays show improved diagnostic and prognostic performance, underscoring its potential as part of multimarker algorithms rather than a stand-alone test. Ongoing efforts to harmonize assays, define reference intervals, and evaluate kinetic behavior in prospective cohorts are essential for translation into practice. Ultimately, CYFRA 21-1 represents a biologically grounded, minimally invasive biomarker capable of enhancing personalized oncology by refining risk stratification, guiding therapeutic decisions, and enabling earlier detection of relapse. Continued validation and clinical integration may establish CYFRA 21-1 as a key component in the evolving landscape of evidence-based cancer management.
References
Barak, V., Goike, H., Panaretakis, K. W., & Einarsson, R. (2004). Clinical utility of cytokeratins as tumor markers. Clinical biochemistry, 37(7), 529–540. https://doi.org/10.1016/j.clinbiochem.2004.05.009
Sheard, M. A., Vojtesek, B., Simickova, M., & Valik, D. (2002). Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. Journal of cellular biochemistry, 85(4), 670–677. https://doi.org/10.1002/jcb.10173
Verma, V., & Rao, R. N. (2022). Cytokeratin 19 expression in intrathoracic neoplasms: First study utilizing cellblocks, evaluating the role of a rarely used cytokeratin for lung cancers. Diagnostic cytopathology, 50(3), 105–111. https://doi.org/10.1002/dc.24927
Ebert, W., Bodenmüller, H., & Hölzel, W. (1995). CYFRA 21-1--clinical applications and analytical requirements. Scandinavian journal of clinical and laboratory investigation. Supplementum, 221, 72–80. https://doi.org/10.3109/00365519509090568
Minamibata, A., Kono, Y., Arimoto, T., Marunaka, Y., & Takayama, K. (2023). Variability of serum CYFRA 21 - 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis. BMC pulmonary medicine, 23(1), 344. https://doi.org/10.1186/s12890-023-02650-x
Bracun, V., Suthahar, N., Shi, C., de Wit, S., Meijers, W. C., Klip, I. T., de Boer, R. A., & Aboumsallem, J. P. (2021). Established Tumour Biomarkers Predict Cardiovascular Events and Mortality in the General Population. Frontiers in cardiovascular medicine, 8, 753885. https://doi.org/10.3389/fcvm.2021.753885
Ashour, A. A., Tayeb, F. J., Felemban, M. F., & Shafie, A. (2025). Nanomaterial-based biosensors for cancer diagnosis: trends and innovations (2022-2025). Mikrochimica acta, 192(7), 404. https://doi.org/10.1007/s00604-025-07276-w
Okamura, K., Takayama, K., Izumi, M., Harada, T., Furuyama, K., & Nakanishi, Y. (2013). Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung cancer (Amsterdam, Netherlands), 80(1), 45–49. https://doi.org/10.1016/j.lungcan.2013.01.002
Bréchot, J. M., Chevret, S., Nataf, J., Le Gall, C., Frétault, J., Rochemaure, J., & Chastang, C. (1997). Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: a prospective study of 116 patients. European journal of cancer (Oxford, England : 1990), 33(3), 385–391.
Yoon, S., Lim, Y. K., Kim, H. R., Lee, M. K., & Kweon, O. J. (2023). Establishment of Reference Intervals of Cytokeratin 19 Fragment Antigen 21-1 in Korean Adults. Annals of laboratory medicine, 43(1), 82–85. https://doi.org/10.3343/alm.2023.43.1.82
Schneider J. (2010). Early detection of lung cancers - Comparison of computed tomography, cytology and fuzzy-based tumor markers panels. Cancer biomarkers : section A of Disease markers, 6(3-4), 149–162. https://doi.org/10.3233/CBM-2009-0126
Kim, Y. C., Lim, S. C., Bom, H. S., Park, K. O., Na, K. J., Park, H. K., & Hwang, J. H. (2000). Different cutoff values of Cyfra 21-1 for cavitary and noncavitary lung cancers. Lung cancer (Amsterdam, Netherlands), 30(3), 187–192. https://doi.org/10.1016/s0169-5002(00)00134-3
Yu, Z., Zhang, G., Yang, M., Zhang, S., Zhao, B., Shen, G., & Chai, Y. (2017). Systematic review of CYFRA 21-1 as a prognostic indicator and its predictive correlation with clinicopathological features in Non-small Cell Lung Cancer: A meta-analysis. Oncotarget, 8(3), 4043–4050. https://doi.org/10.18632/oncotarget.14022
Miyadera, K., Kakuto, S., Sugai, M., Tsugitomi, R., Amino, Y., Uchibori, K., Yanagitani, N., Sugiura, H., Seike, M., Nishio, M., & Ariyasu, R. (2024). Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. Cancers, 16(21), 3712. https://doi.org/10.3390/cancers16213712
Takei, Y., Minato, K., Tsuchiya, S., Takise, A., Nakano, H., Ezawa, K., Fueki, N., Hoshino, H., Naruse, I., Nomoto, T., Makimoto, T., Ishihara, S., Saito, R., & Mori, M. (1997). CYFRA 21-1: an indicator of survival and therapeutic effect in lung cancer. Oncology, 54(1), 43–47. https://doi.org/10.1159/000227660
Yoshimura, A., Uchino, J., Hasegawa, K., Tsuji, T., Shiotsu, S., Yuba, T., Takumi, C., Yamada, T., Takayama, K., & Hiraoka, N. (2019). Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. Translational lung cancer research, 8(3), 227–234. https://doi.org/10.21037/tlcr.2019.06.08
Bi, H., Yin, L., Fang, W., Song, S., Wu, S., & Shen, J. (2023). Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with Clinicopathological Characteristics and Chemotherapeutic Outcomes of Lung Cancer. Laboratory medicine, 54(4), 372–379. https://doi.org/10.1093/labmed/lmac122
Niklinski, J., Burzykowski, T., Niklinska, W., Laudanski, J., Chyczewski, L., Rapellino, M., & Furman, M. (1998). Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. The European respiratory journal, 12(6), 1424–1428. https://doi.org/10.1183/09031936.98.12061424
Cabrera-Alarcon, J. L., Carrillo-Vico, A., Santotoribio, J. D., Leon-Justel, A., Sanchez-Gil, R., Gonzalez-Castro, A., & Guerrero, J. M. (2011). CYFRA 21-1 as a tool for distant metastasis detection in lung cancer. Clinical laboratory, 57(11-12), 1011–1014.
Nakao, M., Kinoshita, R., Kuriyama, M., Kiyotoshi, H., Sugihara, M., Takeda, N., Ohtakara, K., & Muramatsu, H. (2024). Serum CYFRA 21-1 Level as a Prognostic Marker for Extensive Disease Small Cell Lung Cancer. Anticancer research, 44(2), 845–851. https://doi.org/10.21873/anticanres.16877
Kataoka, N., Katayama, Y., Yamada, T., Morimoto, K., Takeda, T., Okada, A., Shiotsu, S., Chihara, Y., Hiranuma, O., Yamada, T., Ota, T., Harada, T., Hasegawa, I., Nishioka, N., Iwasaku, M., Tokuda, S., & Takayama, K. (2024). CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study. Translational lung cancer research, 13(8), 1929–1937. https://doi.org/10.21037/tlcr-24-190
Autsavapromporn, N., Duangya, A., Klunklin, P., Chitapanarux, I., Kranrod, C., Jaikang, C., Monum, T., & Tokonami, S. (2025). Combined Serum IL-6 and CYFRA 21-1 as Potential Biomarkers for Radon-Associated Lung Cancer Risk: A Pilot Study. Biomedicines, 13(9), 2145. https://doi.org/10.3390/biomedicines13092145
Liu, L., Xie, W., Xue, P., Wei, Z., Liang, X., & Chen, N. (2019). Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis. PloS one, 14(5), e0216561. https://doi.org/10.1371/journal.pone.0216561
Wang, Y. X., Hu, D., & Yan, X. (2013). Diagnostic accuracy of Cyfra 21-1 for head and neck squamous cell carcinoma: a meta-analysis. European review for medical and pharmacological sciences, 17(17), 2383–2389.
Rudhart, S. A., Langen, P., Thangavelu, K., Gehrt, F., Stankovic, P., Wilhelm, T., Stuck, B. A., & Hoch, S. (2022). Clinical Impact of CYFRA 21-1 a Marker for Treatment Failure in Patients With Oropharyngeal Cancer Treated by Radio(chemo)therapy. Anticancer research, 42(1), 137–146. https://doi.org/10.21873/anticanres.15467
Tokic, L., Hasukic, S., Brkic, F., Umihanic, S., Hukic, F., & Mustafic, S. (2025). The Diagnostic Significance of the Tumor Marker CYFRA 21-1 in Patients with Laryngeal Carcinoma. Materia socio-medica, 37(2), 131–135. https://doi.org/10.5455/msm.2025.37.131-135
Rudhart, S. A., Schultz, J. D., Gehrt, F., Pavel, F. L., Birk, R., Hoch, M., Stuck, B. A., & Hoch, S. (2019). CYFRA 21-1: a suitable tumor marker in patients with head and neck cutaneous squamous cell carcinoma?. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 276(12), 3467–3475. https://doi.org/10.1007/s00405-019-05614-2
Kalfert, D., Ludvik, J., Kucera, R., Topolcan, O., Celakovsky, P., Pesta, M., Kholova, I., Plzak, J., & Ludvikova, M. (2019). Pretreatment Serum Levels of Soluble Cytokeratin Fragments (Cyfra 21-1, TPS, MonoTotal) in Relation to Clinical and Pathobiological Aspects of Head and Neck Squamous Cell Carcinomas. Anticancer research, 39(9), 5171–5177. https://doi.org/10.21873/anticanres.13713
Pradier, O., Hille, A., Schmiberger, H., & Hess, C. F. (2002). Monitoring of therapy in head and neck patients during the radiotherapy by measurement of Cyfra 21-1. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 6(1), 15–21. https://doi.org/10.1016/s1278-3218(01)00110-x
Kuropkat, C., Lippert, B. M., & Werner, J. A. (2002). Follow-up with serum Cyfra 21-1 in patients with squamous cell carcinomas of the head and neck. Oncology, 63(3), 280–285. https://doi.org/10.1159/000065476
Barak, V., Meirovitz, A., Leibovici, V., Rachmut, J., Peretz, T., Eliashar, R., & Gross, M. (2015). The Diagnostic and Prognostic Value of Tumor Markers (CEA, SCC, CYFRA 21-1, TPS) in Head and Neck Cancer Patients. Anticancer research, 35(10), 5519–5524.
Maass, J. D., Hoffmann-Fazel, A., Goeroegh, T., Hoffmann, M., Meyer, J. E., Gottschlich, S., Rudert, H., & Maune, S. (2000). Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer research, 20(3B), 2241–2243.
Doweck, I., Barak, M., Uri, N., & Greenberg, E. (2000). The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. British journal of cancer, 83(12), 1696–1701. https://doi.org/10.1054/bjoc.2000.1502
Shimada, H., Nabeya, Y., Okazumi, S., Matsubara, H., Miyazawa, Y., Shiratori, T., Hayashi, H., Gunji, Y., & Ochiai, T. (2003). Prognostic significance of CYFRA 21-1 in patients with esophageal squamous cell carcinoma. Journal of the American College of Surgeons, 196(4), 573–578. https://doi.org/10.1016/s1072-7515(02)01905-1
Qiao, Y., Chen, C., Yue, J., & Yu, Z. (2019). Tumor marker index based on preoperative SCC and CYFRA 21-1 is a significant prognostic factor for patients with resectable esophageal squamous cell carcinoma. Cancer biomarkers : section A of Disease markers, 25(3), 243–250. https://doi.org/10.3233/CBM-190058
Wakatsuki, M., Suzuki, Y., Nakamoto, S., Ohno, T., Ishikawa, H., Kiyohara, H., Kiyozuka, M., Shirai, K., Nakayama, Y., & Nakano, T. (2007). Clinical usefulness of CYFRA 21-1 for esophageal squamous cell carcinoma in radiation therapy. Journal of gastroenterology and hepatology, 22(5), 715–719. https://doi.org/10.1111/j.1440-1746.2006.04498.x
Shishido, Y., Matsunaga, T., Sawata, S., Makinoya, M., Miyauchi, W., Miyatani, K., Uejima, C., Morimoto, M., Murakami, Y., Hanaki, T., Kihara, K., Yamamoto, M., Tokuyasu, N., Takano, S., Sakamoto, T., Saito, H., Hasegawa, T., & Fujiwara, Y. (2021). Platelet-to-Lymphocyte Ratio Multiplied by the Cytokeratin-19 Fragment Level as a Predictor of Pathological Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. Yonago acta medica, 64(3), 249–259. https://doi.org/10.33160/yam.2021.08.003
Yang, Y., Liu, Z., Jiang, C., Pan, J., Yu, B., Zhu, K., Xu, Y., & Li, Z. (2023). Prognostic Value of Combination of Lymphocyte-to-Monocyte-Ratio and CYFRA 21-1 in Esophageal Squamous Cell Carcinoma. World journal of surgery, 47(12), 3240–3249. https://doi.org/10.1007/s00268-023-07190-3
Yi, Y., Li, B., Wang, Z., Sun, H., Gong, H., & Zhang, Z. (2009). CYFRA21-1 and CEA are useful markers for predicting the sensitivity to chemoradiotherapy of esophageal squamous cell carcinoma. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 14(7), 480–485. https://doi.org/10.3109/13547500903180265
Sunpaweravong, S., Puttawibul, P., Sunpaweravong, P., Nitiruangjaras, A., Boonyaphiphat, P., & Kemapanmanus, M. (2016). Correlation between Serum SCCA and CYFRA 2 1-1, Tissue Ki-67, and Clinicopathological Factors in Patients with Esophageal Squamous Cell Carcinoma. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 99(3), 331–337.
Nakamura, T., Ide, H., Eguchi, R., Hayashi, K., Takasaki, K., & Watanabe, S. (2017). CYFRA 21-1 as a tumor marker for squamous cell carcinoma of the esophagus. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 11(1), 35–39. https://doi.org/10.1093/dote/11.1.35
Yin, N., & Liu, W. (2020). Clinical Value of Tumor Marker Index Based on Preoperative CYFRA 21-1 and SCC-Ag in the Evaluation of Prognosis and Treatment Effectiveness in Patients with Esophageal Squamous Cell Carcinoma. OncoTargets and therapy, 13, 4135–4143. https://doi.org/10.2147/OTT.S243038
Lee J. H. (2013). Clinical Usefulness of Serum CYFRA 21-1 in Patients with Colorectal Cancer. Nuclear medicine and molecular imaging, 47(3), 181–187. https://doi.org/10.1007/s13139-013-0218-4
Lim, D. H., Lee, J. H., & Kim, J. W. (2018). Feasibility of CYFRA 21-1 as a serum biomarker for the detection of colorectal adenoma and advanced colorectal adenoma in people over the age of 45. Journal of clinical laboratory analysis, 32(1), e22163. https://doi.org/10.1002/jcla.22163
Holdenrieder, S., Stieber, P., Liska, V., Treska, V., Topolcan, O., Dreslerova, J., Matejka, V. M., Finek, J., & Holubec, L. (2012). Cytokeratin serum biomarkers in patients with colorectal cancer. Anticancer research, 32(5), 1971–1976.
Li, S., Wei, W., Feng, Z., Bian, Y., Pan, J., Mai, J., Ning, S., Huang, J., Gao, X., & Zhang, L. (2023). Role of Serum CYFRA 21-1 in Diagnosis and Prognostic in Colorectal Liver Metastases. Cancer management and research, 15, 601–614. https://doi.org/10.2147/CMAR.S410477
Hu, W. Q., Cong, H., Fang, R. H., Yuan, W. T., Mao, C. Y., Wang, J. R., Wang, Y., & Shi, X. Y. (2023). Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine], 57(10), 1613–1619. https://doi.org/10.3760/cma.j.cn112150-20230611-00457
Ye, F., Qian, Y., Liu, J., Li, J., Zhang, Y., Li, H., Bei, S., Zhang, X., & Feng, L. (2025). Potential utility of CYFRA 21-1 and neuron-specific enolase molecular structures for the recognition and surveillance of sessile serrated lesions and traditional serrated adenomas. International journal of biological macromolecules, 310(Pt 3), 143476. https://doi.org/10.1016/j.ijbiomac.2025.143476
Liscia, D. S., Detoma, P., Zanchetta, M., Anrò, P., Molinar, D., Favettini, E., & Paduos, A. (2017). The Use of CYFRA 21-1 for the Detection of Breast Cancer Axillary Lymph Node Metastases in Needle Washouts of Fine-Needle Aspiration Biopsies. Applied immunohistochemistry & molecular morphology : AIMM, 25(3), 190–195. https://doi.org/10.1097/PAI.0000000000000287
Choi, J. S., Han, K. H., Kim, E. K., Moon, H. J., Yoon, J. H., & Kim, M. J. (2015). Fine-needle aspirate CYFRA 21-1, an innovative new marker for diagnosis of axillary lymph node metastasis in breast cancer patients. Medicine, 94(19), e811. https://doi.org/10.1097/MD.0000000000000811
Giovanella, L., Ceriani, L., Giardina, G., Bardelli, D., Tanzi, F., & Garancini, S. (2002). Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Clinical chemistry and laboratory medicine, 40(3), 298–303. https://doi.org/10.1515/CCLM.2002.047
Nakata, B., Takashima, T., Ogawa, Y., Ishikawa, T., & Hirakawa, K. (2004). Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer. British journal of cancer, 91(5), 873–878. https://doi.org/10.1038/sj.bjc.6602074
Pierga, J. Y., Deneux, L., Bonneton, C., Vincent-Salomon, A., Nos, C., Anract, P., Magdelénat, H., Pouillart, P., & Thiery, J. P. (2004). Prognostic value of cytokeratin 19 fragment (CYFRA 21-1) and cytokeratin-positive cells in bone marrow samples of breast cancer patients. The International journal of biological markers, 19(1), 23–31. https://doi.org/10.5301/jbm.2008.649
Di Gioia, D., Blankenburg, I., Nagel, D., Heinemann, V., & Stieber, P. (2016). Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clinica chimica acta; international journal of clinical chemistry, 461, 1–7. https://doi.org/10.1016/j.cca.2016.07.014
Treska, V., Topolcan, O., Zoubkova, V., Treskova, I., Narsanska, A., & Kucera, R. (2018). Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases. Anticancer research, 38(6), 3647–3652. https://doi.org/10.21873/anticanres.12640
Hyun, J. W., Shin, H. S., Kim, S. H., Kong, S. Y., Yoo, H., Gwak, H. S., & Kim, H. J. (2020). CYFRA 21-1 levels in cerebrospinal fluid as a putative therapeutic monitoring biomarker for patients with leptomeningeal carcinomatosis: A pilot study. Cancer biomarkers : section A of Disease markers, 28(1), 81–89. https://doi.org/10.3233/CBM-190187
Wang, H., & Yang, X. (2017). Association between serum cytokines and progression of breast cancer in Chinese population. Medicine, 96(49), e8840. https://doi.org/10.1097/MD.0000000000008840
Won, S. Y., Kim, E. K., Moon, H. J., Yoon, J. H., Park, V. Y., & Kim, M. J. (2020). Diagnostic Value of CYFRA 21-1 Measurement in Fine-Needle Aspiration Washouts for Detection of Axillary Recurrence in Postoperative Breast Cancer Patients]. Taehan Yongsang Uihakhoe chi, 81(1), 147–156. https://doi.org/10.3348/jksr.2020.81.1.147
Mai, S., Liu, H., Zeng, H., Cheng, Z., Huang, J., Shi, G., Li, Y., & Wu, Z. (2024). Diagnostic challenge and survival analysis of pulmonary oligometastases and primary lung cancer in breast cancer patients. Thoracic cancer, 15(12), 1017–1028. https://doi.org/10.1111/1759-7714.15285
Giovanella, L., Treglia, G., Verburg, F. A., Salvatori, M., & Ceriani, L. (2012). Serum cytokeratin 19 fragments: a dedifferentiation marker in advanced thyroid cancer. European journal of endocrinology, 167(6), 793–797. https://doi.org/10.1530/EJE-12-0660
Giovanella, L., Ceriani, L., Ghelfo, A., & Maffioli, M. (2008). Circulating cytokeratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland. The International journal of biological markers, 23(1), 54–57. https://doi.org/10.1177/172460080802300109
Jeong, C., Lee, J., Yoon, H., Ha, J., Kim, M. H., Bae, J. S., Jung, C. K., Kim, J. S., Kang, M. I., & Lim, D. J. (2021). Serum CYFRA 21.1 Level Predicts Disease Course in Thyroid Cancer with Distant Metastasis. Cancers, 13(4), 811. https://doi.org/10.3390/cancers13040811
Lee, J., Shin, Y., Kwak, J., Park, H. L., Lee, S., Kim, M. K., Bae, J. S., Jung, C. K., Jung, S. L., Lee, J. M., Chang, S. A., & Lim, D. J. (2025). Validation of Diagnostic Utility of Washout CYFRA 21-1 in Lymph Node Metastasis of Thyroid Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(10), 1922–1930. https://doi.org/10.1158/1078-0432.CCR-24-3562
Giovanella, L., Imperiali, M., & Trimboli, P. (2017). Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer. Scientific reports, 7(1), 7359. https://doi.org/10.1038/s41598-017-07915-0
Malapure, S. S., Patel, C. D., Lakshmy, R., & Bal, C. (2020). Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer. Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India, 35(2), 116–121. https://doi.org/10.4103/ijnm.IJNM_148_19
Matuszczak, M., & Salagierski, M. (2020). Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers. International journal of molecular sciences, 21(9), 3360. https://doi.org/10.3390/ijms21093360
Satyam, A., Singh, P., Sharma, M., Seth, A., & Sharma, A. (2011). CYFRA 21-1: a potential molecular marker for noninvasive differential diagnosis of urothelial carcinoma of bladder. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 16(5), 413–421. https://doi.org/10.3109/1354750X.2011.582152
Andreadis, C., Touloupidis, S., Galaktidou, G., Kortsaris, A. H., Boutis, A., & Mouratidou, D. (2005). Serum CYFRA 21-1 in patients with invasive bladder cancer and its relevance as a tumor marker during chemotherapy. The Journal of urology, 174(5), 1771–1776. https://doi.org/10.1097/01.ju.0000176742.53556.25
Nisman, B., Barak, V., Shapiro, A., Golijanin, D., Peretz, T., & Pode, D. (2002). Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer, 94(11), 2914–2922. https://doi.org/10.1002/cncr.10565
Fernandez-Gomez, J., Rodríguez-Martínez, J. J., Barmadah, S. E., García Rodríguez, J., Allende, D. M., Jalon, A., Gonzalez, R., & Alvarez-Múgica, M. (2007). Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer. European urology, 51(5), 1267–1274. https://doi.org/10.1016/j.eururo.2006.12.019
Views:
0
Downloads:
0
Copyright (c) 2025 Paweł Jurczak, Dominik Małek, Paweł Puczel, Marta Siwek, Klaudia Sztaba
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
